A Phase 1b/2 Open-Label Study to Evaluate the Safety and Efficacy of Lucitanib in Combination with Nivolumab in Patients with an Advanced Metastatic Solid Tumor

Brief description of study

This is an open-label, Phase 1b/2 study to determine the recommended dose of lucitanib in combination with nivolumab in patients with an advanced solid tumor (Phase 1b); followed by evaluation of the safety and efficacy of lucitanib and nivolumab in patients with an advanced gynecological solid tumor (Phase 2). We will enrolling in the Phase II portion of the trial.

Clinical Study Identifier: s19-01154
ClinicalTrials.gov Identifier: NCT04042116

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.